Quick Answer
CytomX Therapeutics, Inc. reported Research And Development Expense of $68.73 million for the year ending 2025.
- CytomX Therapeutics, Inc. showed a decrease of -17.6% in Research And Development Expense from 2024 to 2025.
- This data is from CytomX Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), CytomX Therapeutics, Inc.'s Research And Development Expense has grown by 531.1%.
- Historical annual values: Fiscal year 2025: $68.73 million | Fiscal year 2024: $83.38 million | Fiscal year 2023: $77.68 million | Fiscal year 2022: $111.65 million | Fiscal year 2021: $114.19 million | Fiscal year 2020: $112.94 million | Fiscal year 2019: $131.62 million | Fiscal year 2018: $103.87 million | Fiscal year 2017: $92.28 million | Fiscal year 2016: $54.76 million | Fiscal year 2015: $28.36 million | Fiscal year 2014: $28.30 million | Fiscal year 2013: $10.89 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: